Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437207 | 0.80 | NPSR1 (0.41) | GLAGRIA1GRIA3GAAALDH1A1 | |
| SCHEMBL9014849 | 0.72 | TLR8 (0.34) | GRIA1GRIA3GAA | |
| SCHEMBL9147234 | 0.71 | GAA (0.32) | GRIA1GRIA3GAAKDM4E | |
| SCHEMBL4182412 | 0.70 | TDP1 (0.47) | GLAGAAALDH1A1L3MBTL1TSHR | |
| SCHEMBL3731488 | 0.70 | GRIA1 (0.54) | GRIA1GRIA3ALDH1A1GRIA2GRIA4 | |
| SCHEMBL8555482 | 0.68 | GRIA1 (0.46) | GRIA1GRIA3GAAALDH1A1GRIA2 | |
| SCHEMBL30561963 | 0.67 | MEN1 (0.37) | GAAALDH1A1CACNA1FCACNA1DCACNA1S | |
| SCHEMBL12500526 | 0.67 | P2RX7 (0.44) | GAAALDH1A1L3MBTL1TDP1KMT2A | |
| Propionic Acid SCHEMBL9538907 | 0.67 | GRIA1 (0.40) | GRIA1GRIA3GAAALDH1A1GRIA2 | |
| SCHEMBL21940617 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192931-B2 | Treatment of demyelinating diseases | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-03-20 | — | — | US | claimed |
| EP-1359933-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | Neuronz Limited (NZ) | 2003-11-12 | — | — | EP | claimed |
| WO-2002030448-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030447-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| US-12221493-B2 | Immunotherapy against several tumors including neuronal and brain tumors | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-02-11 | — | — | US | disclosed |
| US-8703799-B2 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120129889-A1 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE (US) | 2012-05-24 | — | — | US | disclosed |
| US-8129414-B2 | Non-competitive NMDA receptor antagonists | Adejare, Adeboye (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011030336-A1 | METHODS OF DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-03-17 | — | — | WO | disclosed |
| EP-1952797-A1 | Use of a cosmetic composition comprising NMDA receptor agonists for cosmetic skin treatment | Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080039498-A1 | Non-competitive NMDA receptor antagonists | ADEJARE ADEBOYE | 2008-02-14 | — | — | US | disclosed |
| WO-2007149508-A2 | NON-COMPETITIVE NMDA RECEPTOR ANTAGONISTS | THE UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1196448-A2 | HOMOMERIC AND HETEROMERIC AMPA RECEPTORS | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001002549-A2 | HOMOMERIC AND HETEROMERIC AMPA RECEPTORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-1996012725-A1 | NOVEL QUINOXALINDIONE DERIVATIVES, THEIR PRODUCTION AND USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-05-02 | — | — | WO | disclosed |
| EP-0633779-A1 | USE OF $g(b)-CARBOLINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020820-A1 | USE OF β-CARBOLINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993004687-A1 | USE OF PREGNENOLONE SULFATE AND DERIVATIVES FOR THE TREATMENT OF CNS DISEASES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039498-A1 | Non-competitive NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2A | GLA 4363/4885GRIA1 23/4885GRIA3 19/4885 |
| US-20120129889-A1 | Non-competitive NMDA receptor antagonists | GRIN1, GRIN3A, GRIN2A | GLA 4363/4885GRIA1 23/4885GRIA3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.